Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents.
American ginseng and its ginsenoside constituents have been shown to exert anti-cancer effects although the mechanism of action remains unclear. The present study determined the effects of water-extracted ginseng (GE) or its ginsenoside (GF) and polysaccharide (PS) fractions on the proliferation of human colon cancer cells and examined the role of p21 in mediating these effects using wild-type and p21-/- HCT116 human colon carcinoma cells. Proliferation was inhibited by GE, GF, and PS in wild-type and p21-/- cells, and the p21-/- cells were more sensitive to these treatments. Wild type cells treated with GE were arrested in the G0/G1 phase of the cell cycle and the expression of p53 and p21 proteins was increased while phospho-MEK levels decreased. In contrast, cells deficient in p21 displayed reduced cell viability, elevated number of dead cells, and increased expression of Bax and cleaved caspase-3 proteins. Both polysaccharides and ginsenosides appear to be responsible for the anti-proliferative and proapoptotic effects of GE. This study suggests that p21 functions to arrest HCT116 wild-type cells treated with GE, while p21-deficient cells undergo cell death in a ginseng constituent-dependent manner.
King
M L
ML
Southern Illinois University, School of Medicine, Department of Physiology, Carbondale, IL 62901, USA. mwalters@siumed.edu
Murphy
L L
LL
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism*; D036145:Ginsenosides / Q000494:pharmacology / Q000627:therapeutic use*; D045325:HCT116 Cells; D006801:Humans; D005894:Panax / Q000737:chemistry*; D010770:Phosphotransferases / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D018517:Plant Roots; D011134:Polysaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D050759:Cyclin-Dependent Kinase Inhibitor p21; D036145:Ginsenosides; D010936:Plant Extracts; D011134:Polysaccharides; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D010770:Phosphotransferases; D053148:Caspase 3
Phytomedicine. 2002 Jul;9(5):398-404
12222658
J Nutr. 2007 Jan;137(1 Suppl):183S-185S
17182823
Cancer Causes Control. 2000 Jul;11(6):565-76
10880039
Arch Pharm Res. 2004 Jan;27(1):61-7
14969341
Cancer Chemother Pharmacol. 2007 Jun;60(1):69-79
17009031
Arch Pharm Res. 2004 Apr;27(4):429-35
15180309
Cancer Lett. 2005 Dec 18;230(2):228-38
16297709
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Oncogene. 2006 Feb 16;25(7):972-80
16331277
J Pharmacol Sci. 2004 Jun;95(2):153-7
15215638
Int J Oncol. 2007 Nov;31(5):1149-56
17912442
Chem Biodivers. 2006 Feb;3(2):187-97
17193257
Adv Data. 2004 May 27;(343):1-19
15188733
J Korean Med Sci. 2001 Dec;16 Suppl:S81-6
11748382
J Biol Chem. 2005 Sep 9;280(36):32018-25
16002406
Am J Chin Med. 2007;35(1):169-82
17265560
Carcinogenesis. 2005 Aug;26(8):1450-6
15831530
Altern Med Rev. 2004 Sep;9(3):259-74
15387718
Immunopharmacol Immunotoxicol. 2002 Aug;24(3):469-82
12375741
Planta Med. 2002 Feb;68(2):119-22
11859460
Science. 1998 Nov 20;282(5393):1497-501
9822382
J Biol Chem. 2002 May 10;277(19):17154-60
11877436
Cancer Res. 2006 Dec 1;66(23):11254-62
17145870
Carcinogenesis. 2008 Dec;29(12):2351-9
18802031
J Pharmacol Sci. 2006 Mar;100(3):175-86
16518078
Drug Metab Dispos. 2003 Aug;31(8):1065-71
12867496
Cancer Chemother Pharmacol. 1994;33(4):291-7
8281621
Integr Cancer Ther. 2006 Sep;5(3):236-43
16880429
Free Radic Biol Med. 2006 Aug 15;41(4):601-9
16863993
Oncol Rep. 2009 Mar;21(3):577-84
19212614
J Korean Med Sci. 2001 Dec;16 Suppl:S54-60
11748377
J Med Food. 2004 Spring;7(1):1-6
15117545
J Biol Chem. 2002 Oct 4;277(40):37949-54
12151395
Planta Med. 2007 Jun;73(7):669-74
17538869
Life Sci. 2006 Feb 16;78(12):1336-40
16288926
Eur J Cancer. 2000 Jun;36(10):1303-9
10882871
Life Sci. 2000 Aug 4;67(11):1297-306
10972198
Mol Cell Biochem. 2000 Jan;203(1-2):1-10
10724326
Methods Enzymol. 1994;230:1-15
8139491
Am J Chin Med. 2005;33(3):397-404
16047557
J Exp Ther Oncol. 2007;6(2):147-55
17407973
Cancer Res. 2005 May 15;65(10):3980-5
15899785
Exp Mol Med. 2006 Jun 30;38(3):325-31
16819292
Drug Resist Updat. 2003 Aug;6(4):183-95
12962684
Int J Oncol. 1999 May;14(5):869-75
10200336
Toxicol Appl Pharmacol. 2004 Feb 1;194(3):221-9
14761678